Skip to main content

Advertisement

SpringerLink
Log in

Recommendations on current approach to gastric cancer

  • Special Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The management of gastric cancer has been updated by the Grupo Español de Tratamiento de Tumores Digestivos (TTD). A multidisciplinary approach is essential in these patients including a precise diagnosis and staging and correct nutritional evaluation. For resectable disease, surgical resection remains the treatment mainstay and both perioperatory chemotherapy and postoperatory chemoradiotherapy are considered standard complementary treatments. In advanced disease chemotherapy should always be considered. There are different reference schemes (TCF, XC, ECF, EXC) and the therapeutic option has to be individualised. Recently a phase III trial has shown a significant improvement in overall survival when trastuzumab is added to cisplatin-capecitabine or cisplatin-5-fluorouracil in patients with HER2+ advanced gastric cancer. Currently, there are several ongoing clinical trials evaluating the role of other new drugs against cellular targets. It would be desirable to incorporate biomarker studies in these trials in order to identify the best treatment for each patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592

    Article  PubMed  CAS  Google Scholar 

  2. Área de Epidemiología Ambiental y Cáncer. Centro Nacional de Epidemiología Instituto de Salud Carlos III. La situación del cáncer en España. Ministerio de Sanidad y Consumo

  3. Cunningham D, Jost LM, Purkalne G, Oliveira J, coordinating authors for the ESMO Guidelines Task Force (2005) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Ann Oncol 16[Suppl 1]:22–23

    Article  Google Scholar 

  4. Sobin LH, Wittekind C (eds) (2002) TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York

    Google Scholar 

  5. Bozzetti F (2002) Rationale and indications for preoperative feeding of malnourished surgical cancer patients. Nutrition 18:953–959

    Article  PubMed  Google Scholar 

  6. Corish CA (1999) Pre-operative nutritional assessment. Proc Nutr Soc 58:821–829

    Article  PubMed  CAS  Google Scholar 

  7. Barrera R (2002) Nutritional support in cancer patients. JPEN J Parenter Enteral Nutr 26[5 Suppl]:S63–71

    Article  PubMed  Google Scholar 

  8. Kruizenga HM, Van Tulder MW, Seidell JC et al (2005) Effectiveness and cost-effectiveness of early screening and treatment of malnourished patients. Am J Clin Nutr 82:1082–1089

    PubMed  CAS  Google Scholar 

  9. Brennan MF, Karpeh MS Jr (1996) Surgery for gastric cancer: the American view. Semin Oncol 23:352

    PubMed  CAS  Google Scholar 

  10. Robertson CS, Chung SC, Woods SD et al (1994) A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 220:176–182

    Article  PubMed  CAS  Google Scholar 

  11. Gouzi JL, Huguier M, Fagniez PL et al (1989) Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 209:162–166

    Article  PubMed  CAS  Google Scholar 

  12. Bozzetti F, Marubini E, Bonfanti G et al (1999) Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial — Italian Gastrointestinal Tumor Study Group. Ann Surg 230:170–178

    Article  PubMed  CAS  Google Scholar 

  13. Bonenkamp JJ, Songun I, Hermans J et al (1995) Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 345:745–748

    Article  PubMed  CAS  Google Scholar 

  14. Cuschieri A, Fayers P, Fielding J et al (1996) Postoperative morbidity and mortality after R1 and R2 resection for gastric cancer: results of the MRC surgical trial. Lancet 347:995–999

    Article  PubMed  CAS  Google Scholar 

  15. Jansen EPM, Boot H, Verheij M, van de Velde CJ (2005) Optimal locoregional treatment in gastric cancer. J Clin Oncol 23:4509–4517

    Article  PubMed  Google Scholar 

  16. Hermans J, Bonenkamp JJ, Boon MC et al (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11:1441–1447

    PubMed  CAS  Google Scholar 

  17. Earle CC, Maroun JA (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35:1059–1064

    Article  PubMed  CAS  Google Scholar 

  18. Mari E, Floriani I, Tinazzi A et al (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente. Ann Oncol 11:837–843

    Article  PubMed  CAS  Google Scholar 

  19. Panzini I, Gianni L, Fattori PP et al (2002) Adjuvant chemotherapy in gastric cancer: a metaanalysis of randomized trials and a comparison with previous meta-analysis. Tumori 88:21–27

    PubMed  CAS  Google Scholar 

  20. Janunger KG, Hafstrom L, Glimelius B (2002) Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 168:597–608

    Article  PubMed  CAS  Google Scholar 

  21. Sakamoto J Paoletti X, on behalf of the Global Adv/Adj Stomach Tumor Research through International Collaboration (GASTRIC) (2008) Metaanalyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy in gastric cancer. J Clin Oncol 26[18 Suppl]:abstr 4543

  22. Sakuramoto S, Sasako M, Yamaquchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820

    Article  PubMed  CAS  Google Scholar 

  23. Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730

    Article  PubMed  CAS  Google Scholar 

  24. Macdonald JS, Benedetti J, Smalley S et al (2009) Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 27[18 Suppl]:abstr 4515

  25. Macdonald JS, Smalley S, Benedetti J et al (2004) Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup Study INT-0116 (SWOG 9008). 2004 Gastrointestinal Cancers Symposium. Abstr 6

  26. Cunningham D, Allum WH, Stening SP, Weeden S (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

    Article  PubMed  CAS  Google Scholar 

  27. Boige V, Pignon J, Saint-Aubert B et al (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07 FFCD 9703 trial. J Clin Oncol 25[18 Suppl]:abstr 4510

  28. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909

    Article  PubMed  CAS  Google Scholar 

  29. Sastre J, Garcia-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 14:204–213

    Google Scholar 

  30. Rivera F, Vega-Villegas ME, López-Brea M (2007) Chemotherapy of advanced gastric cancer. Cancer Treat Rev 33:315–324

    Article  PubMed  CAS  Google Scholar 

  31. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and 5FU vs 5FU, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267

    PubMed  CAS  Google Scholar 

  32. Vanhoefer U, Rougier P, Wilke H et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and 5FU versus infusional 5FU and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648–2657

    PubMed  CAS  Google Scholar 

  33. Ajani JA, Fodor MB, Tjulandin SA et al (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660–5667

    Article  PubMed  CAS  Google Scholar 

  34. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    Article  PubMed  CAS  Google Scholar 

  35. Roth AD, Fazio N, Stupp R et al (2007) Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25:3217–3223

    Article  PubMed  CAS  Google Scholar 

  36. Cunningham D, Starling N, Rao S et al (2008) Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46

    Article  PubMed  CAS  Google Scholar 

  37. Kang Y, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666–673

    Article  PubMed  Google Scholar 

  38. Chun J, Kim H, Lee J et al (2005) Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 28:188–194

    Article  PubMed  CAS  Google Scholar 

  39. Lorenzen S, Duyster J, Lersch C et al (2005) Three-weekly docetaxel (T) plus capecitabine (X) in 1st and 2nd line metastatic esophageal cancer (MEC): final results of the phase II DACAPO Trial. J Clin Oncol 23[16 Suppl]:abstr 4142

  40. Kim J, Sohn S, Kim D et al (2005) Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 68:190–195

    Article  PubMed  CAS  Google Scholar 

  41. Thuss-Patience P, Kretzschmar A, Loew A et al (2005) Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing Phase II study. J Clin Oncol 23:abstr 4224

    Google Scholar 

  42. Giordano K, Jatoi A, Stella P et al; North Central Cancer Treatment Group (2006) Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a Phase II study from the North Central Cancer Treatment Group. Ann Oncol 17:652–656

    Article  PubMed  CAS  Google Scholar 

  43. Dank M, Zaluski J, Barone C et al (2008) Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19:1450–1457

    Article  PubMed  CAS  Google Scholar 

  44. Ajani JA, Rodriquez W, Bodoky G et al (2009) Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset analyses. J Clin Oncol 27[15 Suppl]:abstr 4511

  45. Thuss-Patience PC, Kretzschmar A, Deist T et al (2009) Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 27[Suppl 18]:abstr 4540

  46. Tabernero J (2008) Molecular therapies in esophageal and gastric cancer. Are we on target? Gastrointestinal Cancers Symposium, ASCO, Orlando, FL, 17–18

    Google Scholar 

  47. Pinto C, Di Fabio F, Siena S et al (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastro-esophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510–517

    Article  PubMed  CAS  Google Scholar 

  48. Lordick F, Lorenzen S, Hegewisch-Becker S et al (2007) Cetuximab plus weekly oxaliplatin/5FU/LV in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. J Clin Oncol 25:abstr 4526

    Google Scholar 

  49. Tanner M, Hollmen M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273–278

    Article  PubMed  CAS  Google Scholar 

  50. Lordick F, Bang YJ, Kang YK et al (2007) HER2-positive advanced gastric cancer similar HER2-positivity levels to breast cancer. Eur J Cancer 5:271

    Google Scholar 

  51. Grávalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523–1529

    Article  PubMed  Google Scholar 

  52. Gravalos C, Márquez A, García-Carbonero R et al (2007) Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Gastrointestinal Cancers Symposium abstr 89

  53. Van Cutsem E, Kang Y, Chung H et al (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27[18 Suppl]:abstr LBA4509

  54. Rech J, Arnold D, Folprecht G et al (2006) A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. ESMO abstr 1096

  55. Enzinger PC, Ryan DP, Regan EM et al (2008) Phase II trial of docetaxel, cisplatin, irinotecan and bevacizumab in metastatic esophagogastric cancer. Gastrointestinal Cancers Symposium abstr 97

  56. Shah MA, Ramanathan RK, Ilson D et al (2006) Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447). J Clin Oncol 24:5201–5206

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Marqués de Valdecilla University Hospital, Avda. Valdecilla, s/n, ES-39008, Santander, Spain

    Fernando Rivera

  2. Hospital Ramón y Cajal, Madrid, Spain

    Alfredo Carrato

  3. Hospital 12 de Octubre, Madrid, Spain

    Cristina Grávalos

  4. Hospital de Sabadell, Corporación Sanitaria Parc Taulí, Barcelona, Spain

    Carles Pericay

  5. Hospital Clínico San Carlos, Madrid, Spain

    Javier Sastre

  6. Hospital Reina Sofía, Córdoba, Spain

    Enrique Aranda

Authors
  1. Fernando Rivera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfredo Carrato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Grávalos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carles Pericay
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Javier Sastre
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Enrique Aranda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernando Rivera.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rivera, F., Carrato, A., Grávalos, C. et al. Recommendations on current approach to gastric cancer. Clin Transl Oncol 11, 518–525 (2009). https://doi.org/10.1007/s12094-009-0396-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-009-0396-9

Keywords

Search

Navigation